Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice

J Cyst Fibros. 2017 Nov;16(6):671-680. doi: 10.1016/j.jcf.2017.05.003. Epub 2017 May 20.

Abstract

Background: Epithelial sodium channel (ENaC, Scnn1) hyperactivity in the lung leads to airway surface dehydration and mucus accumulation in cystic fibrosis (CF) patients and in mice with CF-like lung disease.

Methods: We identified several potent ENaC specific antisense oligonucleotides (ASOs) and tested them by inhalation in mouse models of CF-like lung disease.

Results: The inhaled ASOs distributed into lung airway epithelial cells and decreased ENaC expression by inducing RNase H1-dependent degradation of the targeted Scnn1a mRNA. Aerosol delivered ENaC ASO down-regulated mucus marker expression and ameliorated goblet cell metaplasia, inflammation, and airway hyper-responsiveness. Lack of systemic activity of ASOs delivered via the aerosol route ensures the safety of this approach.

Conclusions: Our results demonstrate that antisense inhibition of ENaC in airway epithelial cells could be an effective and safe approach for the prevention and reversal of lung symptoms in CF and potentially other inflammatory diseases of the lung.

Keywords: Aerosol; Antisense oligonucleotide; Cystic fibrosis; ENaC.

MeSH terms

  • Administration, Inhalation
  • Animals
  • Cystic Fibrosis* / metabolism
  • Cystic Fibrosis* / physiopathology
  • Disease Models, Animal
  • Epithelial Sodium Channel Blockers / pharmacology
  • Epithelial Sodium Channels / metabolism*
  • Mice
  • Oligonucleotides, Antisense / pharmacology*
  • Respiratory Mucosa* / metabolism
  • Respiratory Mucosa* / physiopathology
  • Respiratory System Agents / pharmacology
  • Treatment Outcome

Substances

  • Epithelial Sodium Channel Blockers
  • Epithelial Sodium Channels
  • Oligonucleotides, Antisense
  • Respiratory System Agents